Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:08:16 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for C:GUD from 2023-05-03 to 2024-05-02 - 30 items News ReleasesIn The NewsOther CAUS
DateSymCompanyPriceTypeHeadline
2024-03-27 08:10C:GUDKnight Therapeutics Inc5.44SEDAR Annual ReportSEDAR Annual Report
2024-03-22 07:58C:GUDKnight Therapeutics Inc5.27In the NewsGlobe says Knight seen "as a good long-term investment"
2024-03-21 13:42C:GUDKnight Therapeutics Inc5.23SEDAR MD & ASEDAR MD & A
2024-03-21 10:45C:GUDKnight Therapeutics Inc5.39News ReleaseKnight Therapeutics loses $16.83-million in 2023
2024-03-21 07:50C:GUDKnight Therapeutics Inc5.39SEDAR Annual Information FormSEDAR Annual Information Form
2024-03-21 07:50C:GUDKnight Therapeutics Inc5.39SEDAR MD & ASEDAR MD & A
2024-03-21 07:45C:GUDKnight Therapeutics Inc5.39SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-03-14 08:26C:GUDKnight Therapeutics Inc5.28News ReleaseKnight Therapeutics to release 2023 results March 21
2024-03-07 07:52C:GUDKnight Therapeutics Inc5.51In the NewsGlobe says Knight Therapeutics kept at "outperform"
2024-02-29 12:43C:GUDKnight Therapeutics Inc5.55News ReleaseKnight Therapeutics rolls out Minjuvi in Brazil
2024-02-21 17:53C:GUDKnight Therapeutics Inc5.41News ReleaseKnight applies for fostamatinib marketing nod in Brazil
2024-02-06 11:27C:GUDKnight Therapeutics IncNews ReleaseKnight Therapeutics rolls out Bijuva capsules in Canada
2024-01-25 10:34C:GUDKnight Therapeutics Inc5.51News ReleaseKnight Therapeutics licenses IPX203 from Amneal
2024-01-04 10:31C:GUDKnight Therapeutics Inc5.36News ReleaseKnight Therapeutics rolls out IMVEXXY in Canada
2023-12-19 10:49C:GUDKnight Therapeutics Inc5.15News ReleaseKnight Therapeutics licenses Qelbree from Supernus
2023-11-09 13:48C:GUDKnight Therapeutics Inc4.78News ReleaseKnight Therapeutics earns $9.58-million in Q3
2023-11-09 10:05C:GUDKnight Therapeutics Inc4.78SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-09 10:05C:GUDKnight Therapeutics Inc4.78SEDAR Interim MD & ASEDAR Interim MD & A
2023-11-02 13:39C:GUDKnight Therapeutics Inc4.61News ReleaseKnight Therapeutics to release Q3 2023 results Nov. 9
2023-10-16 10:29C:GUDKnight Therapeutics Inc4.65News ReleaseKnight to roll out Minjuvi in Brazil in Q2 2024
2023-10-10 17:02C:GUDKnight Therapeutics Inc4.63News ReleaseKnight submits pemigatinib application to ANVISA
2023-08-10 13:21C:GUDKnight Therapeutics Inc4.84News ReleaseKnight Therapeutics earns $1.84-million in Q2 2023
2023-08-10 08:01C:GUDKnight Therapeutics Inc4.83SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-03 20:38C:GUDKnight Therapeutics Inc4.75News ReleaseKnight Therapeutics to release Q2 results Aug. 10
2023-07-12 11:36C:GUDKnight Therapeutics Inc4.88News ReleaseKnight Therapeutics to buy back up to 5.99M shares
2023-05-11 11:28C:GUDKnight Therapeutics Inc4.81News ReleaseKnight Therapeutics loses $3.93-million in Q1 2023
2023-05-11 07:42C:GUDKnight Therapeutics Inc4.71SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-05-11 07:42C:GUDKnight Therapeutics Inc4.71SEDAR MD & ASEDAR MD & A
2023-05-10 20:50C:GUDKnight Therapeutics Inc4.71News ReleaseKnight Therapeutics holders elect 7 directors at AGM
2023-05-04 12:41C:GUDKnight Therapeutics Inc4.66News ReleaseKnight Therapeutics to release Q1 results May 11